ProfileGDS5678 / 1417696_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 87% 88% 86% 85% 85% 88% 88% 86% 86% 84% 86% 86% 86% 85% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.5964387
GSM967853U87-EV human glioblastoma xenograft - Control 26.8578888
GSM967854U87-EV human glioblastoma xenograft - Control 36.4702586
GSM967855U87-EV human glioblastoma xenograft - Control 46.6213785
GSM967856U87-EV human glioblastoma xenograft - Control 56.4810185
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.6703488
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.620788
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.4706586
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.5196486
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.2023784
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.5211486
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.5243986
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.4706286
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.2780685